Viralgen’s Post

Check out our recent publication in Cell & Gene Therapy Insights in collaboration with Bio-Techne. In this article, Anthony Blaszczyk and I talk about the current methods for rAAV analytics on Full/Empty and purity assessment by Capillary Electrophoresis.

#Article now available! Evaluation and performance of an #AAVaffinityresin: a #CDMO case study There are now six #AAV-based #genetherapy products on the market, with many more in the R&D pipeline, which has led to an increased demand for the development of efficient and robust downstream purification processes to ensure the production of high-quality AAV vectors. This article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable #downstreampurification of a range of #AAVserotypes for gene therapy applications. Read this article at your convenience below:

#Article now available! Evaluation and performance of an #AAVaffinityresin: a #CDMO case study There are now six #AAV-based #genetherapy products on the market, with many more in the R&D pipeline, which has led to an increased demand for the development of efficient and robust downstream purification processes to ensure the production of high-quality AAV vectors. This article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable #downstreampurification of a range of #AAVserotypes for gene therapy applications. Read this article at your convenience below: https://buff.ly/4dlDmLN

𝗗𝗶𝗱 𝗬𝗼𝘂 𝗞𝗻𝗼𝘄? rcAAV assays are capable of detecting even a single replication-competent virus particle in a large batch of AAV vectors. 🧬This ultra-sensitive detection is 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 for preventing potential complications in patients receiving gene therapy, ensuring that every treatment is as safe and effective as possible. 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝘄𝗲 𝗰𝗮𝗻 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀? Download our latest white paper, 𝘈𝘥𝘢𝘱𝘵𝘪𝘯𝘨 𝘢 𝘳𝘤𝘈𝘈𝘝 𝘈𝘴𝘴𝘢𝘺 𝘧𝘰𝘳 𝘊𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘔𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘪𝘯𝘨, to learn more about our innovative approaches and how we’re setting new standards in the industry. Download here: https://lnkd.in/e6WcPmzz   Partner with SK pharmteco to achieve your gene therapy goals with the peace of mind that comes from knowing your vectors are rigorously tested and safe. Together, we can push the boundaries of innovation and deliver life-changing therapies to those who need them most. #TestingTuesday #AnalyticalServices #rcAAV #ViralVector #CDMO #GeneTherapy

💡Is Charles River Laboratories the right #CDMO partner for you? ➡ Supported the development of 86% of #FDA approved drugs over last 5 years ➡ Supported the development of 11 FDA approved #cellandgene therapies ➡ Integrated platform and service portfolio Incl. #Research, #Discovery, #Safety, #Testing and #Regulatory ➡ 30+ years of integrated #CGT testing and manufacturing capabilities Incl. #plasmid and #viralvector ➡ Founded in 1947 #science #research #lifesciences #biotechnology #scienceandtechnology #genetherapy

Delighted to share the published article by Pharmaron's Spyros Gerontas, Snr. Technical Specialist and Thermo Fisher Scientific entitled '𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗼𝗳 𝗮𝗻 𝗔𝗔𝗩 𝗔𝗳𝗳𝗶𝗻𝗶𝘁𝘆 𝗥𝗲𝘀𝗶𝗻: 𝗔 𝗖𝗗𝗠𝗢 𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆'. The article introduces POROS™ CaptureSelect™ AAVX affinity resins for the scalable downstream purification of a range of AAV serotypes for GT applications, along with Pharmaron's case study analysing the performance of the resin. Check out the article below ⬇ on Cell & Gene Therapy Insights website. #cdmo #aav #genetherapies #AAVXaffinityresins #downstreamprocessing #pharmaron

Using nucleases with high off-target editing… Everything is not 'fine' when you have high off-target editing caused by inefficient nucleases. Off-targets could: -result in unpredictable genetic outcomes...like a zebrafish disease model developing an unwanted third eye 👀 👁️ 🐟 -impact reliability of the results, producing false positives or false negatives ❌ ➕ ➖ -Stall your cell and gene therapy development 😢 What if there was a high-fidelity nuclease that results in minimized off-target editing other common nucleases cannot achieve, extinguishing your #crispr experimental pains (metaphorically speaking, of course, 🧯 )? Check out the link in the comments to learn more about this high-fidelity nuclease 👇

How can you be sure you're meeting regulatory standards for residual host cell DNA in your cell or gene therapy product? Find out here: https://lnkd.in/gVEf9acS HEK293 cells are a commonly used platform for cell and gene therapy production, but traces of DNA from these host cells can be a dangerous potential contaminant in therapeutic products. Droplet Digital PCR technology offers an efficient and sensitive approach for residual host cell DNA detection, enabling absolute quantification of nucleic acid contaminants. Bio-Rad's Vericheck ddPCR HEK293 Residual DNA Detection Kits support a user-friendly workflow for precise measurement of host cell DNA to ensure every product batch adheres to regulatory guidelines. Learn more: https://lnkd.in/grUJZFea #CellTherapy #GeneTherapy #QualityControl #ddPCR

Join our webinar next week to learn about development of a #nonviral CAR-T manufacturing process. #celltherap #cellengineering #CRISPR

Enhancing bystander effects through EV-mRNA cargo in AAV gene replacement therapy: in their latest study, Tierra Bobo at University of North Carolina at Chapel Hill and collaborators created a rAAV vector with a 25 nt EV-mRNA zip code sequence linked to human HGSNAT cDNA to enhance bystander effects, aiming to develop an effective rAAV9 gene replacement therapy for treating MPS IIIC https://lnkd.in/egwA3d4K These results strongly support the therapeutic potential of this novel rAAV gene therapy for MPS IIIC. The authors believe this approach could broadly target diseases involving non-secreted proteins or transcription factors, addressing safety concerns related to high vector doses. An article co-authored by Michael Robinson, Christopher Tofade, Marina Sokolsky-Papkov, Pete Nichols, Stephen Vorobiov and Haiyan Fu #extracellularvesicles #exosomes #AAV #genetherapy #mRNA #Vesiculab